AGIO Agios Pharmaceuticals Inc

Price (delayed)

$45.67

Market cap

$3.16B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.92

Enterprise value

$3.42B

Sector: Healthcare
Industry: Biotechnology

Highlights

Agios Pharmaceuticals's gross profit has surged by 74% YoY and by 4.6% QoQ
The revenue has surged by 73% year-on-year and by 4.7% since the previous quarter
The quick ratio has soared by 79% year-on-year but it is down by 28% since the previous quarter
Agios Pharmaceuticals's equity has decreased by 14% QoQ but it has increased by 7% YoY

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
69.26M
Market cap
$3.16B
Enterprise value
$3.42B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.57
Price to sales (P/S)
16.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.59
Earnings
Revenue
$194.59M
EBIT
-$332.06M
EBITDA
-$313.91M
Free cash flow
-$355.69M
Per share
EPS
-$4.92
Free cash flow per share
-$5.14
Book value per share
$6.95
Revenue per share
$2.81
TBVPS
$13.14
Balance sheet
Total assets
$908.45M
Total liabilities
$428M
Debt
$365.42M
Equity
$480.45M
Working capital
$599.32M
Liquidity
Debt to equity
0.76
Current ratio
9.59
Quick ratio
9.01
Net debt/EBITDA
-0.83
Margins
EBITDA margin
-161.3%
Gross margin
98.9%
Net margin
-170.6%
Operating margin
-169.4%
Efficiency
Return on assets
-37.2%
Return on equity
-57.6%
Return on invested capital
-36.3%
Return on capital employed
-39.6%
Return on sales
-170.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
-0.61%
1 week
-0.35%
1 month
32.8%
1 year
-9.04%
YTD
5.4%
QTD
5.4%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$194.59M
Gross profit
$192.46M
Operating income
-$329.64M
Net income
-$332.06M
Gross margin
98.9%
Net margin
-170.6%
Agios Pharmaceuticals's gross profit has surged by 74% YoY and by 4.6% QoQ
The revenue has surged by 73% year-on-year and by 4.7% since the previous quarter
The operating margin has surged by 54% year-on-year and by 10% since the previous quarter
The net margin has surged by 52% year-on-year and by 7% since the previous quarter

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.57
P/S
16.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.59
Agios Pharmaceuticals's EPS has increased by 28% YoY and by 7% QoQ
The P/B is 31% above the last 4 quarters average of 5.0 and 19% above the 5-year quarterly average of 5.5
Agios Pharmaceuticals's equity has decreased by 14% QoQ but it has increased by 7% YoY
The revenue has surged by 73% year-on-year and by 4.7% since the previous quarter
AGIO's P/S is 59% below its 5-year quarterly average of 39.7 and 8% below its last 4 quarters average of 17.6

Efficiency

How efficient is Agios Pharmaceuticals business performance
Agios Pharmaceuticals's return on sales has surged by 52% YoY and by 7% QoQ
The company's return on invested capital rose by 37% YoY and by 14% QoQ
The ROA has grown by 27% YoY and by 8% from the previous quarter
AGIO's return on equity is up by 18% year-on-year and by 3.5% since the previous quarter

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The total assets is 112% greater than the total liabilities
AGIO's current ratio has surged by 81% year-on-year but it is down by 27% since the previous quarter
The quick ratio has soared by 79% year-on-year but it is down by 28% since the previous quarter
The debt is 24% smaller than the equity
The debt to equity has soared by 192% YoY and by 17% QoQ
Agios Pharmaceuticals's equity has decreased by 14% QoQ but it has increased by 7% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.